Organization
Department of Immunology and Oncology, Clínica Universidad de Navarra
18 abstracts
Abstract
First-in-human dose-escalation trial of BI 764532, a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager in patients (pts) with DLL3-positive (DLL3+) small-cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC).Org: Technical University Dresden, Medical Faculty, NCT/UCC Early Clinical Trial Unit, Department of Medical Oncology, Vall d'Hebron University Hospital & Vall d'Hebron Institute of Oncology, Washington University School of Medicine, Department of Immunology and Oncology, Clínica Universidad de Navarra, Cancer Research Program, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques),
Abstract
Neoadjuvant therapy using PD-1 inhibitor plus chemotherapy with different intervals between chemotherapy cycles for locally advanced gastric or gastroesophageal junction cancer: A randomized phase 2 study.Org: Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Henan Cancer Hospital, Department of Immunology and Oncology, Clínica Universidad de Navarra, Henan Cancer Hosptal, Surgical Oncology, Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University,
Abstract
First-in-human dose-escalation trial of BI 764532, a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager in patients (pts) with DLL3-positive (DLL3+) small-cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC).Org: Technical University Dresden, Medical Faculty, NCT/UCC Early Clinical Trial Unit, NCT/UCC Early Clinical Trial Unit, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Institute of Oncology,
Abstract
Clinical development of the bispecific PSMAxCD3 antibody CC-1.Org: University Hospital Tübingen, German Cancer Consortium (DKTK), Partner Site Munich, Department of Internal Medicine, Clinical Collaboration Unit Translational Immunology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital and German Cancer Research Center (DKFZ),
Abstract
EO2401 (E) peptide immunotherapy + nivolumab (N) +/- bevacizumab (B) in recurrent glioblastoma (GB): EOGBM1-18/ROSALIE.Org: Universitätsklinikum Heidelberg, German Cancer Research Center, Sorbonne Université, AP-HP at Saint-Louis Hospital, ICM,
Abstract
Interim results from a phase I/II study of duvelisib PI3Kδγ inhibitor and nivolumab in patients with advanced unresectable melanoma who have progressed on anti-PD1 therapy.Org: University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA, Washington University School of Medicine in St Louis, St. Louis, MO, Department of Immunology and Oncology, Clínica Universidad de Navarra,
Abstract
Safety and survival in adult women with platinum sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Bayindir Sogutozu Hospital, Istanbul University Dep of Oncology, Hacettepe University Faculty of Medicine Department of Medical Oncology, Istanbul University Cerrahpasa Faculty of Medicine,
Abstract
Expression of lymphoid structure-associated cytokine/chemokine gene transcripts in tumor and protein in serum: Outcomes for patients with melanoma.Org: H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, Jordan University of Science and Technology, Irbid, Jordan, UPMC Health Plan,
Abstract
Effect of reducing the number of neoadjuvant chemoimmunotherapy cycles on clinical efficacy in locally advanced PD-L1 positive gastric cancer: A single center phase 2 study.Org: Department of Immunology and Oncology, Clínica Universidad de Navarra, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Henan Cancer Hospital, Department of Gastrointestinal Surgery, The Affiliated Nanchong Central Hospital of North Sichuan Medical College, Nanchong, China, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan,
Abstract
ARTERIAL STIFFNESS IN RHEUMATOID ARTHRITIS PATIENTS AS A POTENTIAL PREDICTOR OF EARLY CARDIOVASCULAR AGEING AND MORBIDITYOrg: Palacky University Olomouc and University Hospital Olomouc, University Hospital Olomouc, Department of Internal Medicine III - Nephrology, Rheumatology and Endocrinology, Department of Immunology and Oncology, Clínica Universidad de Navarra,
Abstract
ASSOCIATION BETWEEN POLYMORPHISMS IN BETA-ADDUCIN AND SODIUM/CALCIUM EXCHANGER 1 AND SLE WITH AND WITHOUT NEPHRITIS Org: Università Vita-Salute S. Raffaele, Milan, Italy, Department of Immunology and Oncology, Clínica Universidad de Navarra, Department of Nephrology, Ospedale San Raffaele, Milano, Italy,
Abstract
A DECREASE IN NEUTROPHIL COUNTS FOLLOWING A SINGLE INFUSION OF TOCILIZUMAB IS PREDICTIVE OF LOW DISEASE ACTIVITY AND REMISSION AFTER 24 WEEKS Org: Department of Immunology and Oncology, Clínica Universidad de Navarra, Department of Rheumatology, University Clinic of Cologne, Department of Statistics, University of Cologne, Köln, Germany,
Abstract
A NEW TYPE OF MONOCLONAL ANTIBODY TO CD4 FOR THE THERAPY OF RHEUMATOID ARTHRITIS (RA)Org: Immunology and Combinations, GlaxoSmithKline, Diaclone SAS, Besancon, France, Laboratory of Clinical Pharmacology,
Abstract
A PROSPECTIVE STUDY OF EARLY RHEUMATOID ARTHRITIS IN SOUTH AFRICA: RESPONSE TO TRADITIONAL DMARDS IN AN IMPOVERISHED SETTINGOrg: Department of Medicine, Icahn School of Medicine at Mount Sinai, University of the Witwatersrand, Johannesburg, South Africa, Department of Immunology and Oncology, Clínica Universidad de Navarra, University of Pretoria, Epidemiology Data Centre,
Abstract
An Analysis of Fatigue in Patients With Psoriatic Disease Utilizing SF-36 Vitality Scores: Results Through Week 24 in Phase 3 Trials of Guselkumab in Patients With Psoriasis and Psoriatic ArthritisOrg: Harvard Medical School, Brigham and Women’s Hospital, Department of Dermatology, Janssen Global Services, LLC, Department of Immunology and Oncology, Clínica Universidad de Navarra,
Abstract
ANTINEUTROPHILIC CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS AND HYPOCOMPLEMENTEMIA: CLINICAL IMPACT AND OUTCOME Org: Department of Internal medicine №1, Department of Immunology and Oncology, Clínica Universidad de Navarra, Department of Nephrology, CHU Côte de Nacre, Caen, France,
Abstract
ANTI-TNF THERAPY FOR IMMUNE MEDIATED INFLAMMATORY DISEASES MAY BE ASSOCIATED WITH LOWER ANTIBODY LEVELS AND VIRUS NEUTRALIZATION EFFICACY FOLLOWING SARS-CoV-2 mRNA VACCINATIONOrg: University Health Network, Schroeder Arthritis Institute, Rheumatology, Toronto, Canada, University of Toronto, Division Of Rheumatology, Department Of Internal Medicine, Toho University School Of Medicine, Tokyo, Japan, Department of Medicine, University of Alberta, Alberta, Canada,
Abstract
ANTIPHOSPHOLIPID ANTIBODIES AND COGNITIVE DYSFUNCTION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUSOrg: Department of Internal Diseases, Division of Hematology, Ege University Medical Faculty Hospital, Izmir, Turkey, Department of Immunology and Oncology, Clínica Universidad de Navarra, Medical University - Sofia, Department of Psychology, Health & Technology, University of Twente, Sofia University,